Rocket says FDA alignment sets path for Danon disease pivotal trial completion by mid-2027
Rocket Pharmaceuticals reported third-quarter 2026 results alongside regulatory and pipeline updates across its cardiovascular gene therapy programs.
Rocket Pharmaceuticals said on September 15, 2026, it reached FDA alignment on continued enrollment and dosing and on key elements of the global pivotal Phase 2 trial of RP-A501 in Danon disease, including a recalibrated dose, a 12-patient pivotal population and established 12-month co-primary endpoints.1 Under that design, at least seven of the 12 patients must show myocardial LAMP2 expression at Grade 1 or higher together with at least a 10% drop from baseline in left ventricular mass index at the 12-month mark to meet the trial's efficacy criterion, with the co-primary endpoints meant to support a possible accelerated approval route.1 The company said it expects to complete pivotal trial dosing by mid-2027, with topline results anticipated in mid-2028.1
For RP-A601 in PKP2-ACM, the ongoing Phase 1 study continues to enroll patients to assess biological activity across a wider range of disease severity.1 Earlier Phase 1 data showed increased PKP2 protein expression, improved desmosomal localization, and directional gains in arrhythmia measures and right ventricular function.1
Rocket also reported it initiated dosing in a Phase 1, multicenter, dose-escalation trial of RP-A701 for BAG3-associated dilated cardiomyopathy, evaluating safety, biological activity and preliminary efficacy in adults.1 On October 20, 2026, the European Commission granted RP-A701 orphan designation for BAG3-DCM.1
On the commercial side, Rocket achieved commercial readiness for KRESLADI on October 1, 2026, with two Qualified Treatment Centers activated and its external manufacturing network in place.1
The company disclosed a new financing arrangement: on October 6, 2026, it entered a credit facility with Hercules Capital for up to $150 million, receiving $35 million at closing, with an additional $35 million optionally available, $30 million tied to a Danon clinical milestone, and $50 million subject to Hercules' investment committee approval.1
Rocket reported cash, cash equivalents and investments of $279.4 million as of September 30, 20261, and said based on its current operating plan, this is expected to fund operations into the third quarter of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.